Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 12Lymphoma, Non-Hodgkin 8Wilms Tumor 7Sarcoma 7Glioma 7Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroblastoma 6Multiple Myeloma 6Medulloblastoma 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Rhabdomyosarcoma 5Osteosarcoma 5Central Nervous System Neoplasms 5Pancreatic Neoplasms 4Mouth Neoplasms 4Leukemia, Myeloid, Acute 4Colorectal Neoplasms 4Breast Neoplasms 4Sarcoma, Ewing 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Cancer, Papillary 2

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Breast Carcinoma × X-Rays × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡